Farzana Jasmine

Staff Scientist

University of Chicago
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

Many non-coding variants influence complex traits and diseases through gene regulation, yet the mechanisms linking these variants to downstream biology remain poorly understood. Here, we present eQTLGen Phase 2 , a comprehensive genome-wide analysis of gene expression quantitative trait loci (eQTLs) in 43,301 blood samples from 52 datasets. Beyond local cis -effects, this sample size enabled the first systematic mapping of trans -eQTLs at scale. We identify cis -eQTLs for nearly all expressed genes (94.7%) and trans -eQTLs for over half (56.2%). Second, by colocalizing cis -eQTLs with trans -eQTLs, we infer a directed gene regulatory network comprising 47,554 directed gene regulatory relationships. These networks reveal how genetic perturbations in upstream regulators produce dose-dependent downstream effects, supported by Perturb-seq and ChIP-seq data. Third, integrating this network with 87 genome-wide association studies allows us to systematically prioritize trait-relevant pathways and candidate genes. Variants exerting both cis – and trans -effects are markedly more likely to colocalize with trait associations than cis -only variants, delineating a subset of functionally active cis -eQTLs from a large group with limited downstream impact. This distinction provides a conceptual framework for identifying regulatory variants that truly mediate complex trait biology. Together, these results provide a publicly available resource of cis – and trans -eQTLs and an in vivo scaffold for human gene-regulatory networks, elucidating how propagation of cis -effects modulates complex disease.

Year:

2026

Background: Studies on somatic mutations in cancer typically report single-nucleotide variants in coding regions, while mutations in short tandem repeats (STRs) are usually overlooked. Homopolymeric regions, a subset of STRs, are stretches of DNA where only a single nucleotide is repeated multiple times (e.g., AAAAA or TTTTT). Only recently have mutations in such STR regions been seen in colorectal cancer, where microsatellite instability (MSI) is common. In non-melanoma skin cancer (NMSC), MSI is rare. In this study, we focus on somatic mutations in such homopolymeric regions in NMSC and their functional implications. Methods: We performed targeted DNA sequencing (paired tissue and blood from the same individual), using more than 400 cancer-related genes from 32 NMSC patients as cases and non-lesional skin tissue from 16 independent individuals as controls. Results: We identified NMSC-associated STR somatic mutations. These are associated with the dysregulation of DNA damage and repair mechanisms. In artificial intelligence (AI) predictive modeling, these markers could successfully differentiate basal cell carcinoma (BCC) and non-lesional skin tissue. To our knowledge, we present the first study focusing on STR somatic mutations in multiple cancer-related genes in NMSC found only in tumor tissue and not in non-lesional skin tissue. Some of them (APC, BRAF) are associated with more pronounced dysregulation of relevant gene pathways (hedgehog, Notch signaling, and Wnt signaling). Conclusions: Our findings suggest that this STR somatic mutation status might potentially be used to select BCC patients who could benefit from certain precision therapy including hedgehog inhibitors, gamma-secretase inhibitors, anti-Vasuclar endothelial growth factor (VEGF), proteasome inhibitors, and immune check-point inhibitors.

Year:

2025

Arsenic (As) is a risk factor for non-melanoma skin cancer (NMSC). From a six-year follow-up study on 7000 adults exposed to As, we reported the associations of single-nucleotide variation in tumor tissue and gene expression. Here, we identify the associations of small deletions (DELs) and transcriptomic profiles in NMSC. Comparing the (a) NMSC tissue (n = 32) and corresponding blood samples from each patient, and (b) an independent set of non-lesional, healthy skin (n = 16) and paired blood, we identified NMSC-associated DELs. Differential expressions of certain gene pathways (TGF-β signaling pathway, IL-17 pathway, PD-L1 pathway, etc.) showed significant interactions with these somatic DELs and As exposure. In low-As-exposure cases, the DELs in APC were associated with the up-regulation of inflamed T-Cell-associated genes by a fold change (FC) of 8.9 (95% CI 4.5–17.6), compared to 5.7 (95% CI 2.9–10.8) without APC DELs; in high-As-exposure cases, the APC DELs were associated with an FC of 5.8 (95% CI 3.5–9.8) compared to 1.2 (95% CI −1.3 to 1.8) without APC DELs. We report, for the first time, the significant associations of somatic DELs (many in STR regions) in NMSC tissue and As exposure with many dysregulated gene pathways. These findings may help in selecting groups of patients for potential targeted therapy like PD-L1 inhibitors, IL-17 inhibitors, and TGF-β inhibitors in the future.

Year:

2025

In colorectal carcinoma (CRC), 5-fluorouracil (5-FU) remains the cornerstone of adjuvant systemic therapy, with folic acid (FA) serving as an essential adjunct. Expression of genes related to the metabolism and action of 5-FU and FA can be influenced by patient- and tumor-specific biological factors. In this study, we explore differential gene expression profiles of 180 genes representing 14 different gene sets associated with different 5-FU and FA metabolism processes, at both gene and pathway levels across clinical and molecular subgroups. In 71 patients with CRC, paired tumors and normal colonic tissues were analyzed. In CRC tissue, several gene sets (including Cell Cycle Checkpoint, Oxidative Stress Response, and Signaling Pathway, etc.) were upregulated, while three gene sets (Apoptotic, Tumor Suppressor, and Endoplasmic Reticulum Stress) were downregulated. Kirsten rat sarcoma virus (KRAS), tumor protein p53 (TP53), and microsatellite instability (MSI) status impacted gene expression across molecular subgroups. At the individual gene level, among cell cycle genes, the BUB3 mitotic checkpoint protein (BUB3) was upregulated in MSI tumors compared to MSS, whereas SMAD family member 4 (SMAD4) was downregulated in MSS tumors compared to MSI. DNA fragmentation factor alpha (DFFA) was downregulated in MSI and upregulated in MSS. Notably, thymidylate synthetase (TYMS) was more upregulated in MSI tumors (1.65-fold; 95% CI: 1.27–2.13) compared to MSS (1.19-fold; 95% CI: 1.02–1.39). Dysregulation of these genes across these factors will broaden our understanding of 5-FU-based treatment in CRC. Furthermore, targeting dysregulated pathways could form the basis for improved precision therapies tailored to CRC subtypes.

Year:

2025

Kirsten Rat Sarcoma (KRAS) is the most commonly mutated oncogene in colorectal carcinoma (CRC). We have previously reported the interactions between microsatellite instability (MSI), DNA promoter methylation, and gene expression. In this study, we looked for associations between KRAS mutation, gene expression, and methylation that may help with precision medicine. Genome-wide gene expression and DNA methylation were done in paired CRC tumor and surrounding healthy tissues. The results suggested that (a) the magnitude of dysregulation of many major gene pathways in CRC was significantly greater in patients with the KRAS mutation, (b) the up- and down-regulation of these dysregulated gene pathways could be correlated with the corresponding hypo- and hyper-methylation, and (c) the up-regulation of CDKN2A was more pronounced in tumors with the KRAS mutation. A recent cell line study showed that there were higher CDKN2A levels in 5-FU-resistant CRC cells and that these could be down-regulated by Villosol. Our findings suggest the possibility of a better response to anti-CDKN2A therapy with Villosol in KRAS-mutant CRC. Also, the more marked up-regulation of genes in the proteasome pathway in CRC tissue, especially with the KRAS mutation and MSI, may suggest a potential role of a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) in selected CRC patients if necessary.

Year:

2024

Exposure to inorganic arsenic (As) is recognized as a risk factor for non-melanoma skin cancer (NMSC). We followed up with 7000 adults for 6 years who were exposed to As. During follow-up, 2.2% of the males and 1.3% of the females developed basal cell carcinoma (BCC), while 0.4% of the male and 0.2% of the female participants developed squamous cell carcinoma (SCC). Using a panel of more than 400 cancer-related genes, we detected somatic mutations (SMs) in the first 32 NMSC samples (BCC = 26 and SCC = 6) by comparing paired (tissue–blood) samples from the same individual and then comparing them to the SM in healthy skin tissue from 16 participants. We identified (a) a list of NMSC-associated SMs, (b) SMs present in both NMSC and healthy skin, and (c) SMs found only in healthy skin. We also demonstrate that the presence of non-synonymous SMs in the top mutated genes (like PTCH1, NOTCH1, SYNE1, PKHD1 in BCC and TP53 in SCC) significantly affects the magnitude of differential expressions of major genes and gene pathways (basal cell carcinoma pathways, NOTCH signaling, IL-17 signaling, p53 signaling, Wnt signaling pathway). These findings may help select groups of patients for targeted therapy, like hedgehog signaling inhibitors, IL17 inhibitors, etc., in the future.

Year:

2024

Background and Objective: In sporadic colorectal carcinomas (CRC), microsatellite instability (MSI) pathways play important roles. Previously, we showed differences in DNA methylation patterns in microsatellite stable (MSS) colorectal carcinomas and MSI-CRC. In the current study, we explore the similarities and differences in gene expression profiles in MSS and MSI at the gene level and at the pathway level to better understand CRC pathogenesis and/or the potential for therapeutic opportunities. Material and Methods: Seventy-one CRC patients (MSI = 18, MSS = 53) were studied. Paired tumor and adjacent normal tissues were used for genome-wide gene expression assays. Result: At the gene level, we compared the list of differentially expressed genes (fold change (FC) ≥ 3 and FDR < 0.05) in tumor tissues compared to corresponding normal tissue in CRC patients with MSI tumors (190 genes) and MSS tumors (129 genes). Of these, 107 genes overlapped. The list of genes that were differentially expressed in MSI tumors only showed enrichment predominantly in two broad categories of pathways—(a) Inflammation-related pathways including the interleukin-17 (IL-17) signaling pathway, tumor necrosis factor (TNF) signaling pathway, chemokine signaling, nuclear factor kappa B (NFκB) signaling, and cytokine-cytokine interactions, and (b) metabolism-related pathways, including retinol metabolism, steroid hormone biosynthesis, drug metabolism, pentose and glucoronate interconversions, and ascorbate and aldarate metabolism. The genes in inflammation-related pathways were up-regulated whereas genes in metabolism-related pathways were down-regulated in MSI tumor tissue. Pathway-level analysis also revealed similar results confirming the gene enrichment findings. For example, the 150 genes involved in the IL-17 signaling pathway were on average up-regulated by 1.19 fold (CI 1.16–1.21) in MSI compared to 1.14 fold (CI 1.13–1.16) in MSS patients (interaction p = 0.0009). Conclusions: We document an association between MSI status and differential gene expression that broadens our understanding of CRC pathogenesis. Furthermore, targeting one or more of these dysregulated pathways could provide the basis for improved therapies for MSI and MSS CRC.

Year:

2024

Residents of Bangladesh are exposed to numerous chemicals due to local industries, including dyeing mills, cotton mills, and the use of biomass in daily cooking. It is, therefore, important to characterize the exposome and work to identify risk factors of exposure. We used silicone wristband passive samplers to evaluate exposure to volatile and semi-volatile organic compounds in a sample of 40 children in the Araihazar upazila of Bangladesh. We used stepwise linear regression models to determine which demographic, exposure, diet, and socioeconomic factors best predict exposure to single chemicals and classes of chemicals. Male sex at birth was associated with a decrease in the number of chemicals detected above their median concentration (β = −2.42; 95%CI: −5.24, 0.399), as was ownership of a flush toilet (β = −3.26; 95%CI: −6.61, 0.097). Increased body mass index (β = 1.81; 95%CI: 0.587, 3.03), father’s smoking (β = 2.74; 95%CI: −0.0113, 5.49), and father’s employment in the garment industry (β = 3.14; 95%CI: 0.209, 6.07) were each associated with an increase in the average number of chemicals detected above their median concentration. The observed results motivate future evaluation with health outcomes of these exposures.

Year:

2024

Year:

2023

Year:

2023

Collaborators (48)

Qingbo Wang

Associate Professor

University of Tokyo

JAPAN
View details

Annique Claringbould

Assistant Professor

Erasmus MC

NETHERLANDS
View details

Marie Loh

Assistant Professor

Lee Kong Chian School of Medicine

SINGAPORE
View details

Javier Martin

Professor

Instituto de Parasitología y Biomedicina López-Neyra

SPAIN
View details

Katie Burnham

University of Oxford

UNITED KINGDOM
View details

Sini Nagpal

Assistant Professor

Indian Institute of Technology, Bombay

View details

Brenda WJH Penninx

Professor

-

NETHERLANDS
View details

René Pool

University of Amsterdam

NETHERLANDS
View details

Markus Scholz

Leipzig University

GERMANY
View details

Marta Eugenia Alarcón Riquelme

Scientific Director

Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica

SPAIN
View details

Laura Raffield

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dirk Paul

Interim Head of PMB BioPharma

AstraZeneca UK Limited

UNITED KINGDOM
View details

Jouke-Jan Hottenga

Senior Researcher

Hamad Bin Khalifa University

QATAR
View details

Roel A. Ophoff

Professor

University of California, Los Angeles

UNITED STATES
View details

Ana Viñuela

Academic, Lecturer (Teaching and Research)

University of Dundee

UNITED KINGDOM
View details

Pashupati Mishra

Tampere University

FINLAND
View details

Christopher Weber

Professor

University of Chicago

UNITED STATES
View details

Emma Elisabeth Davenport

Group Leader

Wellcome Sanger Institute

UNITED KINGDOM
View details

José Manuel Soria Fernández

Principal Investigator. Head of Group

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Julian Knight

University of Oxford

UNITED KINGDOM
View details

Mika Kähönen

University of Tampere

FINLAND
View details

Muhammad Kibriya

Research Associate Professor

University of Chicago

UNITED STATES
View details

Alexander Teumer

Professor

University Medicine Greifswald

GERMANY
View details

Andrew Brown

Principal Investigator

University of Dundee

UNITED KINGDOM
View details

Toni Boltz

Massachusetts General Hospital

UNITED STATES
View details

Zoltán Kutalik

Full Professor

University of Lausanne

SWITZERLAND
View details

Katja Pahkala

Associate professor, Academy research fellow

University of Turku

FINLAND
View details

Emma Raitoharju

Senior Researcher

University of Tampere

FINLAND
View details

Grant Montgomery

Professorial Research Fellow

University of Queensland

AUSTRALIA
View details

Annette Peters

Chair of Epidemiology

Ludwig-Maximilians-Universität München

GERMANY
View details

Kaur Alasoo

Associate Professor

University of Tartu

ESTONIA
View details

Joachim Thiery

Dean of Medicine and UKSH Board for Research snd Education

Kiel University

GERMANY
View details

Alexis Battle

Professor

Johns Hopkins University

UNITED STATES
View details

Holger Kirsten

Leipzig University

GERMANY
View details

Olli T. Raitakari

University of Turku

FINLAND
View details

Christopher Shea

Professor

University of Chicago

UNITED STATES
View details

Uwe Völker

Professor, Head of Department

Universitätsmedizin Greifswald

GERMANY
View details

Jan Veldink

Professor of Neurology and Neurogenetics

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Suvi Rovio

Adjunct professor, senor researcher

University of Turku

FINLAND
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Carla van der Kallen

University of Maastricht

NETHERLANDS
View details

Terho Lehtimäki

University of Tampere

FINLAND
View details

Greg Gibson

Regents Professor

Georgia Tech

UNITED STATES
View details

Yukinori Okada

University of Tokyo

JAPAN
View details

Marleen van Greevenbroek

University of Maastricht

NETHERLANDS
View details

Yun Li

Professor

University of North Carolina

UNITED STATES
View details

Dorret I Boomsma

Full professor

University of Amsterdam

NETHERLANDS
View details

Takanori Hasegawa

Associate Professor

Institute of Science Tokyo

JAPAN
View details